DGAP-News

Evotec and CHDI Foundation expand ongoing collaboration to fight Huntington's disease using Evotec's expanded capabilities and footprint

DGAP-News: Evotec AG / Key word(s): Alliance
Evotec and CHDI Foundation expand ongoing collaboration to fight
Huntington's disease using Evotec's expanded capabilities and
footprint

02.09.2015 / 07:31

---------------------------------------------------------------------

Hamburg, Germany - 02 September 2015: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) today announced that CHDI Foundation, Inc.
("CHDI") has extended and expanded its collaboration with Evotec through to
August 2018. Over this period CHDI will fund 55 full-time scientists at
Evotec. The collaboration-which aims to find new treatments for
Huntington's disease, an inherited neurodegenerative disorder-will take
advantage of additional technologies, capabilities and capacities at
Evotec's facilities in Toulouse, France, and Princeton, NJ, USA.

The collaboration was initiated in 2006 and has grown considerably over
this period to fully utilise Evotec's best-in-class integrated neuroscience
platform. The extension of this collaboration is a further validation of
Evotec's investment in new technologies and capabilities in support of
driving innovative drug discovery collaborations. Evotec provides CHDI with
a full range of research activities and expertise in the neuroscience area,
including integrated biology and chemistry supported by compound and
library management, target validation, stem cell research, high-content
screening, computational chemistry, in vitro pharmacokinetics and protein
production.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are
delighted to continue our collaboration with CHDI and this extension
clearly illustrates that CHDI values our commitment to expanding both our
capabilities and capacity. We look forward to continuing working closely
with our colleagues at CHDI to rapidly discover novel drugs against
Huntington's disease targets."

"Evotec represents one of our largest and longest standing relationships
and continues to be an important strategic partner in our search for
meaningful therapies for Huntington's disease families", added Dr Robert
Pacifici, Chief Scientific Officer at CHDI. "Their integrated drug
discovery capabilities are helping us discover novel targets and to advance
drug candidates towards the clinic and we look forward to continuing to
work with Evotec over the coming years."


ABOUT HUNTINGTON'S DISEASE
Huntington's disease is a familial disease caused by a mutation in the
huntingtin gene. Each child of a parent with the mutation in the huntingtin